Financials EUROAPI

Equities

EAPI

FR0014008VX5

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 11:35:19 2024-04-26 am EDT			5-day change	1st Jan Change
2.76 ^EUR	+6.32%		+2.91%	-51.83%

Apr. 10	Euroapi Names New Chief Commercial Officer	MT
Apr. 10	Euroapi: tightening of executive committee	CF

Valuation

Fiscal Period: December	2022	2023	2024	2025	2026
Capitalization ¹	1,302	543.9	261.8	-	-
Enterprise Value (EV) ¹	1,348	734.9	364.8	289.8	261.8
P/E ratio	-86.6 x	-2.84 x	-3.19 x	-22.2 x	7.75 x
Yield	-	-	-	0.27%	10.4%
Capitalization / Revenue	1.33 x	0.54 x	0.29 x	0.27 x	0.26 x
EV / Revenue	1.38 x	0.73 x	0.4 x	0.3 x	0.26 x
EV / EBITDA	11.2 x	7.89 x	7.32 x	3.03 x	2.05 x
EV / FCF	-11 x	-5.75 x	5.07 x	106 x	5.75 x
FCF Yield	-9.09%	-17.4%	19.7%	0.94%	17.4%
Price to Book	1.17 x	0.59 x	0.3 x	0.28 x	0.27 x
Nbr of stocks (in thousands)	94,010	94,913	94,838	-	-
Reference price ²	13.85	5.730	2.760	2.760	2.760
Announcement Date	3/8/23	2/28/24	-	-	-

¹EUR in Million²EUR

Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December	2021	2022	2023	2024	2025	2026
Net sales ¹	-	976.6	1,013	917	968.8	1,004
EBITDA ¹	-	120	93.1	49.85	95.65	127.9
EBIT ¹	-	47.3	16.7	-18.51	34.76	57.25
Operating Margin	-	4.84%	1.65%	-2.02%	3.59%	5.7%
Earnings before Tax (EBT) ¹	-	3.1	-242.8	-73.66	-40.44	28.37
Net income ¹	-15.8	-15	-189.7	-81.94	-11.88	33.43
Net margin	-	-1.54%	-18.72%	-8.94%	-1.23%	3.33%
EPS ²	-0.1800	-0.1600	-2.020	-0.8655	-0.1244	0.3559
Free Cash Flow ¹	-	-122.6	-127.7	71.95	2.733	45.5
FCF margin	-	-12.55%	-12.6%	7.85%	0.28%	4.53%
FCF Conversion (EBITDA)	-	-	-	144.34%	2.86%	35.59%
FCF Conversion (Net income)	-	-	-	-	-	136.11%
Dividend per Share ²	-	-	-	-	0.007500	0.2858
Announcement Date	4/29/22	3/8/23	2/28/24	-	-	-

¹EUR in Million²EUR

Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December	2022 S1	2022 S2	2023 S1	2023 S2
Net sales ¹	483.8	492.8	496.6	516.6
EBITDA ¹	70.3	49.7	62.5	30.6
EBIT ¹	35.6	11.7	26.4	-9.7
Operating Margin	7.36%	2.37%	5.32%	-1.88%
Earnings before Tax (EBT)	-	-	-	-
Net income	-	-	-	-
Net margin	-	-	-	-
EPS	-	-	-	-
Dividend per Share	-	-	-	-
Announcement Date	9/1/22	3/8/23	8/1/23	2/28/24

¹EUR in Million

Estimates

Balance Sheet Analysis

Fiscal Period: December	2021	2022	2023	2024	2025	2026
Net Debt ¹	-	46.3	191	103	28	-
Net Cash position ¹	-	-	-	-	-	-
Leverage (Debt/EBITDA)	-	0.3858 x	2.052 x	2.066 x	0.2927 x	-
Free Cash Flow ¹	-	-123	-128	72	2.73	45.5
ROE (net income / shareholders' equity)	-	3.77%	0.64%	-4.66%	-0.82%	2.74%
ROA (Net income/ Total Assets)	-	2.39%	0.39%	-3.3%	-1.13%	1.31%
Assets ¹	-	-628.1	-48,787	2,479	1,053	2,562
Book Value Per Share ²	-	11.80	9.670	9.170	9.900	10.10
Cash Flow per Share ²	-	0.4700	0.0500	1.450	0.6400	1.090
Capex ¹	-	167	133	123	114	95
Capex / Sales	-	17.14%	13.11%	13.37%	11.74%	9.46%
Announcement Date	4/29/22	3/8/23	2/28/24	-	-	-

¹EUR in Million²EUR

Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for EUROAPI

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

2.76 EUR

Average target price

4.72 EUR

Spread / Average Target

+71.01%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
EUROAPI	-51.83%	279M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals